Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179003 | 0.86 | ESR1 (0.41) | MAPK1ESR1ALDH1A1MEN1KMT2A | |
| SCHEMBL1179629 | 0.82 | HCAR2 (0.39) | ESR1ALDH1A1MEN1KMT2AHCAR2 | |
| SCHEMBL1178889 | 0.82 | ESR1 (0.61) | ESR1HCAR2 | |
| SCHEMBL1179363 | 0.81 | L3MBTL1 (0.41) | MAPK1ESR1ALDH1A1MEN1KMT2A | |
| SCHEMBL1180045 | 0.79 | MAPK1 (0.47) | MAPK1ALDH1A1KMT2ACYP1A2SMN1; SMN2 | |
| SCHEMBL1180153 | 0.78 | ESR1 (0.44) | ESR1MEN1KMT2ACYP1A2HCAR2 | |
| SCHEMBL1178563 | 0.72 | ESR1 (0.42) | ESR1ALDH1A1MEN1KMT2AHCAR2 | |
| SCHEMBL17281038 | 0.71 | KMO (0.45) | MAPK1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1178898 | 0.70 | KDM4E (0.43) | ALDH1A1SMN1; SMN2HCAR2ALOX15TSHR | |
| SCHEMBL10130004 | 0.69 | NOS3 (0.50) | MEN1KMT2ASMN1; SMN2HCAR2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-24 | — | — | US | disclosed |
| CN-101965346-A | Novel pyrimidine-pyridine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046170-A1 | NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES | TYMP, DPYD, ENTPD5 | MAPK1 1679/4885ESR1 3891/4885ALDH1A1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.